Oral cancer chemotherapy in paediatric patients: obstacles and potential for development and utilisation.
Although most cancer chemotherapy in children is administered parenterally, oral formulations are becoming increasingly available for use in patients as young as infants. Incentives for this approach include safety, flexibility, reduced financial cost, improved quality of life, and the potential for improved efficacy. The ability to deliver chemotherapy at home and apply schedules of administration that increase the agent's efficacy because patients do not require hospitalisation or visits to the clinic renders oral chemotherapy particularly attractive. Obstacles to oral chemotherapy in paediatric patients include restrictions in dose size and schedule, uncertain or low bioavailability, adverse effects of malabsorption, and adherence (noncompliance and refusal to take oral chemotherapy). Techniques to overcome most of these limitations are available or can be developed, and lack of an oral formulation can be solved in many instances by the pharmaceutical industry. Future developments in oral chemotherapy should not be limited to adult patient applications.
Bleyer
W A
WA
Division of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. ableyer@mdanderson.org
Danielson
M G
MG
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002986:Clinical Trials as Topic; D004363:Drug Utilization; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents